Johnson & Johnson $JNJ Shares Sold by Beacon Bridge Wealth Partners LLC

Beacon Bridge Wealth Partners LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 22.3% in the second quarter, HoldingsChannel.com reports. The firm owned 1,397 shares of the company’s stock after selling 401 shares during the quarter. Beacon Bridge Wealth Partners LLC’s holdings in Johnson & Johnson were worth $213,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at $218,000. GAMMA Investing LLC lifted its position in shares of Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after acquiring an additional 14,118 shares during the last quarter. Dodds Wealth LLC lifted its position in shares of Johnson & Johnson by 15.6% during the 1st quarter. Dodds Wealth LLC now owns 3,576 shares of the company’s stock valued at $593,000 after acquiring an additional 482 shares during the last quarter. Finally, Founders Grove Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 2.5% during the 1st quarter. Founders Grove Wealth Partners LLC now owns 6,886 shares of the company’s stock valued at $1,142,000 after acquiring an additional 168 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $190.66 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $192.10. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. The stock has a fifty day moving average of $178.48 and a 200-day moving average of $163.77.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion for the quarter. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. HSBC increased their price objective on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Citigroup increased their target price on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $192.94.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.